Viatris Confirms Delay On ‘First And Only’ Botox Biosimilar
Problems For Partner Revance’s Lead Pipeline Candidate Has ‘Direct Impact’
Executive Summary
Viatris remains hopeful of obtaining FDA approval for its proposed biosimilar to Botox in partnership with Revance Therapeutics in 2026, after the latter’s manufacturing problems for another drug candidate stymied development of the rival to the world-renowned cosmetic brand.
You may also be interested in...
Viatris Swats Away Concerns Over Divestment Valuations
Viatris remains committed to completing the sale of its global biosimilars unit to Biocon Biologics, while continuing efforts to generate up to $9bn in pre-tax proceeds by the end of 2023 from divestments.
Viatris Will Not Rule Out Symbicort In 2022 As Trial Looms
Facing down a key patent infringement trial beginning on 19 May, Viatris is continuing to eye an opportunity to launch its Breyna generic version of AstraZeneca’s Symbicort before patent expiry in 2023.
Biocon Pays $3.3bn For Viatris Biosimilars Business
Biocon Biologics will pay up to $3.3bn to acquire the global biosimilars business of Viatris, in a long-rumored deal that will create a vertically-integrated biosimilars giant with annual sales approaching $1bn.